表皮生长因子受体抑制剂对新型冠状病毒感染的潜在治疗价值

Potential value of epidermal growth factor receptor inhibitors in the treatment of COVID-19

新型冠状病毒感染(COVID-19)已在全球持续流行3年余, 影响了人类的健康与经济的发展, 至今特效治疗药物的种类及数目仍然有限。众所周知, 表皮生长因子受体(EGFR)的过度表达或异常的自我活化与多种癌症的发生、发展密切相关。近年来, 已开发出许多以EGFR为靶点的抑制剂并广泛应用于抗肿瘤治疗。然而, 最近的一系列研究表明EGFR在COVID-19等病毒性疾病中也同样扮演着重要角色, 提示表皮生长因子受体抑制剂或可用于抗病毒治疗。本文将重点从表皮生长因子受体抑制剂治疗病毒性疾病的可能机制和疗效进行详细阐述, 以期为COVID-19等病毒性疾病的防治提供新思路。

Coronavirus disease 2019(COVID-19)has been a global epidemic for more than three years,affecting human health and economic development to some extent,and specific treatment is still limited.It is well known that the overexpression or abnormal self-activation of epidermal growth factor receptor(EGFR)is closely related to the progression of various cancers.In recent years,many EGFR inhibitors(EGFRIs)have been developed and widely used in anti-tumor therapy.However,a series of recent studies have shown that EGFR also plays an important role in viral diseases such as COVID-19,suggesting that EGFRIs may be available for antiviral therapy.This review will focus on the potential mechanism and effect of EGFRIs in viral diseases,aiming to provide new ideas for the prevention and treatment of COVID-19 and other viral diseases.